Structure Therapeutics (GPCR) Change in Cash (2022 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Change in Cash of -$483.5 million in Q1 2026, down 169.39% quarter-over-quarter from $696.7 million in Q4 2025, and down 2680.55% on a YoY basis from $18.7 million in Q1 2025.
Structure Therapeutics (GPCR) Change in Cash (2022 - 2026) Analysis & Trends
Structure Therapeutics' Change in Cash history runs 5 years deep, the most recent figure standing at -$483.5 million for Q1 2026.
- In Q1 2026, Change in Cash fell 2680.55% year-over-year to -$483.5 million; the TTM figure through Mar 2026 stood at $164.0 million (up 202.16% YoY), while the FY2025 annual figure was $630.1 million, up 1486.47% from the prior year.
- Change in Cash was -$483.5 million for Q1 2026 at Structure Therapeutics, down from $696.7 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $696.7 million in Q4 2025 to a low of -$483.5 million in Q1 2026.
- Historically, Change in Cash has averaged $12.4 million across 5 years, with a median of -$5.1 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Change in Cash surged 26692.02% in 2025, then sank 2680.55% in 2026.
- A 5-year view of Change in Cash shows it stood at -$2.0 million in 2022, then surged by 4055.82% to $79.2 million in 2023, then plunged by 103.31% to -$2.6 million in 2024, then soared by 26692.02% to $696.7 million in 2025, then sank by 169.39% to -$483.5 million in 2026.
- The last three Change in Cash figures came in at -$483.5 million (Q1 2026), $696.7 million (Q4 2025), and -$44.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 623.00 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 417.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -45.97 Mn |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - | -483.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -483.46 Mn |
| Dec 31, 2025 | 696.71 Mn |
| Sep 30, 2025 | -44.11 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Mar 31, 2025 | -17.39 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Sep 30, 2024 | -209.50 Mn |
| Jun 30, 2024 | 283.80 Mn |
| Mar 31, 2024 | -31.96 Mn |
| Dec 31, 2023 | 79.16 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Jun 30, 2023 | -85.90 Mn |
| Mar 31, 2023 | 100.40 Mn |
| Dec 31, 2022 | -2.00 Mn |
| Sep 30, 2022 | -27.40 Mn |
| Jun 30, 2022 | 4.87 Mn |
| Mar 31, 2022 | -54.68 Mn |